The Medicare Access and CHIP Reauthorization Act represents the biggest change in medicine that I’ve witnessed in my career…. We should seize the opportunity to transform how care is provided from a system we know is broken to one that truly represents quality and value. It’s too...!-->!-->
Positive studies about brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma1 and rituximab (Rituxan) maintenance therapy in mantle cell lymphoma (MCL)2 were reported at the 2016 Annual Meeting of the American Society for Hematology (ASH).
Stephanie Lee, MD
“These abstracts each...!-->!-->
The fact that in the first-line setting, up to 30% of patients can directly get immunotherapy rather than chemotherapy is a major step forward.— Suresh S. Ramalingam, MD
One immune checkpoint inhibitor has now moved to the front of the line for treating advanced...!-->!-->
In November, The University of Texas MD Anderson Cancer Center celebrated its 75th anniversary with a week-long series of events that raised nearly $15 million to support its efforts in patient care and in the investigation and treatment of cancer. Housed on 16 million square feet in the city of...
On November 21, 2016, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior...
Anti–PD-1/PD-L1 will be the backbone upon which all combinations will be based. The only question is whether we will have enough patients to enroll on these combination studies.— Jeffrey Weber, MD, PhD
The future treatment of melanoma may rely on combinations of...!-->!-->
City of Hope and Translational Genomics Research Institute (TGen) have announced an alliance to make precision medicine a reality for patients. This alliance enables both institutes to complement each other in their common areas of research and patient care, with City of Hope providing a...
We found several very subtle differences in tumors between the two populations [those of European vs African ancestry], but the most striking observation was the higher TP53 mutation occurrence in the patients of European ancestry.— Zarko Manojlovic, PhD
Oncologists may be accustomed to looking for commonalities in patients, but highly personalized therapies are now being developed based on mutational analysis of tumors.
According to data presented at the Cedars-Sinai annual symposium on New Therapeutics in Oncology: The Road to Personalized...
Checkpoint inhibitors and targeted therapies are reshaping the landscape of cancer care across multiple tumor sites, but treatments for brain tumors remain decidedly unchanged. The standard of care for high-grade gliomas in the front-line setting—a combination of surgery and chemoradiation—is the...
Only 3% of cancer patients go on clinical trials nationally, which is a huge problem…. We’re not going to cure these diseases if we’re only putting 3% of our patients on trials.— Steven Piantadosi, MD, PhD
In an interview with The ASCO Post, Steven Piantadosi, MD, PhD,...!-->!-->
People who consistently smoked an average of less than 1 cigarette per day over their lifetime had a 64% higher risk of earlier death than never-smokers, and those who smoked between 1 and 10 cigarettes a day had an 87% higher risk of earlier death than never-smokers, according to a new study from...
With drug approvals for immunotherapy in the first- and second-line settings, breakthroughs in targeting epidermal growth factor receptor (EGFR) mutations, and the rapid evolution of therapies that target anaplastic lymphoma kinase (ALK) rearrangements, 2016 has been an extraordinary year for lung...
Barry E. Rosenbloom, MD
Moderator of the session, Barry E. Rosenbloom, MD, Clinical Professor of Medicine at Tower Hematology Oncology Medical Group in Los Angeles, said that the overview of recent advances in lung cancer clearly depicts oncology’s state of flux.
“There are so many...!-->!-->
Cancer experts from the Johns Hopkins Kimmel Cancer Center are now embedded in a newly expanded facility within Johns Hopkins Medicine–owned Sibley Memorial Hospital in northwest Washington, DC.
Sibley recently opened the 30,000-square-foot medical oncology facility—part of its new...
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.
On November 21, 2016, daratumumab (Darzalex) was approved for ...
Randi Kaplan, LMSW
The Schwartz Center for Compassionate Healthcare, a national leader in providing compassionate care to patients and caregivers, has named Randi Kaplan, LMSW, Director of the Arthur D. Emil Caregiver Support Center at Montefiore, the National Compassionate Caregiver of...!-->!-->
The Organizing Committee for the 7th International Cancer Metastasis International Symposium has announced the abstract award winners for the meeting. The winners will be presented during the upcoming meeting, “Cancer Metastasis Through the Lymphovascular System: Biology and Treatment,” to be held...
Ravi Salgia, MD, PhD
City of Hope’s Ravi Salgia, MD, PhD, Chair of the Department of Medical Oncology and Therapeutics Research, has received an accolade that recognizes his decades-long dedication to treating patients with lung cancer and researching new therapies. Dr. Salgia received the ...!-->!-->
No safety outbreaks among generic oncology drugs were reported in developed countries. For developing countries, oversight is less intensive, and concerns around drug safety still exist.— Y. Tony Yang, ScD, and colleagues
In an article in The Lancet Oncology, Y. Tony...!-->!-->
The FDA’s approval process ensures that brand-name and generic drugs meet rigorous standards for safety and efficacy. Postapproval safety surveillance monitoring along with drug product quality testing enables the FDA to ensure drug product safety and quality.
[NSABP B-47] is a key trial. It’s B-31 all over again in HER2-normal breast cancer. Hopefully, we will identify the point at which trastuzumab starts to make a difference, specifically in adjuvant therapy.— Edward H. Romond, MD
Despite the routine use of HER2 blockade...!-->!-->
Adherence to antiemesis guidelines is not very good, especially with highly emetogenic chemotherapy. If you do adhere to the guidelines, you have better control over nausea and vomiting, but choosing wisely is using what you need—and nothing more....!-->!-->— Frankie Ann Holmes, MD
The European Organisation for Research and Treatment of Cancer (EORTC) and the American Association for Cancer Research (AACR) are calling on policymakers and leaders throughout the world to provide robust and sustained funding for cancer research.
The two organizations say there has been a...
Charles Rosser, MD, MBA, FACS
Charles Rosser, MD, MBA, FACS, Professor and Director of the Clinical Trials Office and Director of the Clinical and Translational Research Program at the University of Hawaii Cancer Center, received a 5-year National Cancer Institute (NCI) R01 grant worth...!-->!-->
Christine Laronga, MD, FACS
Christine Laronga, MD, FACS, a surgical oncologist specializing in breast cancer at Moffitt Cancer Center, has been named President of the Association of Women Surgeons. The international organization has more than 1,800 members and represents 21 countries.
Two studies presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich focused on the inhibition of mutations in the KIT and PDGFRα oncogenes. These genes encode receptor tyrosine kinases, and when they are mutated, cell signaling malfunctions, leading to...
Liquid biopsy technologies are increasingly being used to detect genetic mutations in tumors, giving clinicians the opportunity to see in real time how a patient’s cancer may or may not be responding to treatment. In a study presented recently at the 28th EORTC-NCI-AACR Symposium on Molecular...
The trend of higher completion of cancer control behaviors among participants who received navigation was clear: Colorectal cancer screening increased by 40%, mammography increased by 17%, human papillomavirus vaccination of daughters increased by 43%, and participation in smoking ...!-->!-->
James O. Armitage, MD
The University of Nebraska Board of Regents voted to rename an area of the University of Nebraska Medical Center (UNMC) in honor of a longtime professor who has made extraordinary contributions to the institution. The Center for Leukemia and Lymphoma Research,...!-->!-->
Elizabeth M. Swisher, MD, Medical Director of the Breast and Ovarian Cancer Prevention Program at the Seattle Cancer Care Alliance, enjoys developing long-term patient relationships and helping patients who are confronted with cancer and terminal issues. She is particularly interested in the...
According to the National Institutes of Health,1 nearly all patients with head and neck malignancies receiving high-dose radiation therapy; approximately 80% of patients undergoing stem cell transplantation; and about 40% of patients receiving chemotherapy will experience oral complications that...
Fergus J. Couch, PhD
Max S. Wicha, MD
The American Association for Cancer Research (AACR) honored two renowned researchers for their work in breast cancer at the 2016 San Antonio Breast Cancer Symposium (SABCS), held December 6–10 in San Antonio, Texas. Fergus J. Couch, PhD, of...!-->!-->!-->!-->
The National Comprehensive Cancer Network® (NCCN®), a Centers for Medicare & Medicaid Services (CMS)-approved provider-led entity for imaging appropriate use criteria, continues to build its library of these standards and has published NCCN Imaging Appropriate Use Criteria™ for an additional 15 ...
David Tuveson, MD, PhD
David Tuveson, MD, PhD, will succeed Bruce Stillman, AO, FAA, FRS, as Director of the Cold Spring Harbor Laboratory Cancer Center.
Dr. Tuveson is the Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory, the Head of the Lustgarten...!-->!-->
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on immunotherapy as treatment for renal cell carcinoma. These studies are researching combination chemotherapies; immunotherapies; radiosurgery techniques; stereotactic body...
Ellen V. Sigal, PhD
Richard L. Schilsky, MD
The Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA), an independent nonprofit organization that works to advance regulatory science to help support the scientific mission of the FDA, has elected Ellen V. Sigal,...!-->!-->!-->!-->
Roy Wu, PhD
The American Society of Hematology (ASH) recognized Representative David McKinley (R-WV) and Roy Wu, PhD, former Chief of the Clinical Grants and Contracts Branch for the Cancer Therapy Evaluation Program at the National Cancer Institute (NCI), with...!-->!-->!-->!-->
Blood has covered experimental and clinical hematologic research as the flagship journal of the American Society of Hematology (ASH). Launched officially on November 29, 2016, the open-access online journal Blood Advances will fill a niche that complements and expands on topics covered in Blood...
Matthew Campbell, MD, MS
Kevin Courtney, MD, PhD
Thai Ho, MD, PhD
Eliezer Van Allen, MD
Martin Voss, MD
The Kidney Cancer Association has supported 12 kidney cancer research projects through the Conquer Cancer Foundation of ASCO Young...!-->!-->!-->!-->!-->!-->!-->!-->!-->!-->
Priscilla Brastianos, MD
Director, Central Nervous System Metastasis Program
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston
Metastatic brain cancer
People are inspired to pursue careers in cancer research for any number of reasons: They might like the...
We have an incredible opportunity for you to make an amazing impact at the Conquer Cancer Foundation!
An anonymous donor is offering a Matching Gift Challenge, which will double the value of every gift we receive by December 31—dollar for dollar—up to $64,000! This amount is enough to fund...
More than 100 participants are now enrolled on study drug in ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The trial launched in March 2016 at 37 sites, and in November, it welcomed its newest participating clinical sites: Cancer Treatment Centers of America®,...
The Journal of Oncology Practice (JOP) published a special series in its November issue representing the results of a unique project launched in 2014 by ASCO and the National Cancer Institute (NCI) to heighten awareness of ways to enhance team-based care in oncology. Concerns about clinician...
In September 2016, ASCO announced its latest offering to oncology practices: the ability to complete all Physician Quality Reporting System (PQRS) requirements through the user-friendly Quality Oncology Practice Initiative (QOPI®) platform at no cost. By completing the PQRS module by December 31,...
Put trusted, oncologist-approved cancer information in the hands of your patients and their caregivers with Cancer.Net Mobile. This award-winning app helps patients plan and manage their cancer care.
The newest version of Cancer.Net Mobile is optimized for the latest iOS versions and offers ...
Mylin A. Torres, MD
Mylin A. Torres, MD, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University (Winship), was selected to hold the Louisa and Rand Glenn Family Chair in Breast Cancer Research. The endowed position was created by the Wilbur and Hilda...!-->!-->
Dong Moon Shin, MD
Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD, of Yale University, New Haven, Connecticut, was recognized by the International Association for the Study of Lung Cancer (IASLC) with a distinguished award at the 17th World Conference on Lung Cancer in Vienna, Austria. Dr. Herbst accepted the ...!-->!-->
Sean Smith, MD
Physiatry in Oncology explores the benefits of cancer rehabilitation in oncology practice to screen survivors for physical and cognitive impairments along the care continuum to minimize survivors’ disability and maximize their quality of life. The column is...!-->!-->
From Nancy E. Davidson, MD, President of the AACR and Executive Director of the Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, and Margaret Foti, PhD, MD (hc), Chief Executive Officer of the AACR
On behalf of the American Association for Cancer Research (AACR),...
Maura Gillison, MD, PhD
Maura Gillison, MD, PhD, a physician-researcher who has made significant contributions to the fields of cancer biology, therapy, and epidemiology, was elected a member of the National Academy of Medicine during the Academy’s annual meeting. Dr. Gillison is the Jeg...!-->!-->
Launching a new cancer journal is a risky and arduous endeavor, especially for a specialty publication in resource-challenged countries in the developing world. To succeed, a specialty journal must publish articles from established clinical researchers that quickly garner funding and captivate its...
Brandon M. Hayes-Lattin, MD, FACP
Adolescent and Young Adult Oncology explores the unique physical, psychosocial, social, emotional, sexual, and financial challenges adolescents and young adults with cancer face. The column is guest edited by Brandon M. Hayes-Lattin, MD, FACP,...
INSIDE THE BLACK BOX is an occasional column providing insight into the U.S. Food and Drug Administration (FDA) and its policies and procedures. In this installment, Martha Donoghue, MD, Supervisory Medical Officer, and Gregory Reaman, MD, Associate Director for Oncology Sciences in the Office...
Margaret Edson delivers her Keynote Lecture: Wit, Hex, Vin, Life, Death: Using Wit as a Teaching Tool, at the 2016 Palliative Care in Oncology Symposium in San Francisco. Photo ©ASCO/Todd Buchanan 2016.
Among the most widely attended sessions at the 2016 Palliative Care in Oncology...!-->!-->
We need to find ways of integrating palliative care concepts in patients’ usual care experiences, so it isn’t a luxury, but a standard part of health care for those living with serious illness.— Dio Kavalieratos, PhD, and colleagues
People living with serious illness...!-->!-->
In recognition of wide-ranging contributions to the fields of cancer prevention; patient care; and basic, translational, and clinical research, seven faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of...
Matt Ewend, MD, FACS
Allen Daugird, MD, MBA
Matt Ewend, MD, FACS, has been named President of the University of North Carolina (UNC) Physicians. In this role, Dr. Ewend will oversee the physician clinical enterprise of UNC Health Care, which includes more than 2,400 physicians and ...!-->!-->!-->!-->
It is uniformly fatal and impossible to undo. When the chemotherapy drug vincristine is placed in a syringe and injected intrathecally—into the spinal fluid—the patient always dies. And despite safety guidelines and labels, deaths continue to occur.
Now the National Comprehensive Cancer Network®...
Michael R. Kosorok, PhD
University of North Carolina (UNC) Lineberger Comprehensive Cancer Center member Michael R. Kosorok, PhD, has been named a fellow of the American Association for the Advancement of Science (AAAS), the world’s largest general scientific society and publisher of the...!-->!-->
ASCO seeks to guide the future development and implementation of pathways, while addressing stakeholder concerns that have surfaced following the rapid adoption of pathways in oncology.— Daniel F. Hayes, MD, FACP, FASCO
ASCO recently released its Criteria for...!-->!-->
Ellen V. Sigal, PhD
Ellen V. Sigal, PhD, Chair and Founder of Friends of Cancer Research (Friends) began the annual meeting with a conversation with Douglas R. Lowy, MD, National Cancer Institute (NCI) Acting Director, and Robert M. Califf, MD, U.S. Food and Drug Administration (FDA)...!-->!-->
William Sellers, MD
William Sellers, MD, a widely respected cancer researcher with extensive experience in cancer genomics and therapeutic discovery, is returning to the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard, Dana-Farber Cancer Institute, and...!-->!-->
The Leukemia & Lymphoma Society (LLS) has announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute; Weill Cornell Medicine; Memorial...
Steven K. Libutti, MD, FACS
Steven K. Libutti, MD, FACS, has been named the new Director of Rutgers Cancer Institute of New Jersey and will serve as Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences at Rutgers University. When he takes on his new roles in early ...!-->!-->
Janet Riddle, MD
In 2015, Janet Riddle, MD, and her colleagues published an article1 outlining 12 key themes for delineating how fellowship programs in medical education should be developed (See “12 Tips for Developing Successful Fellowship Programs for Medical Educators,” below.)
In its November 2016 issue, the Journal of Oncology Practice (JOP) has published a special series that represents the results of a unique project launched in 2014 by ASCO and the National Cancer Institute (NCI) to heighten awareness of ways to enhance team-based care in oncology. Concerns about...
Tina’s Wish, a nonprofit organization dedicated exclusively to funding scientific research for the early detection of ovarian cancer, recently announced its eight 2017–2018 individual grant recipients after soliciting proposals nationally for the first time. Researchers from Dana-Farber Cancer...
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). For information on how you can submit your own essay for consideration in JCO’s Art of Oncology, visit
2017 Oncologic Emergency Medicine Conference
January 12-13 • Houston, Texas
For more information:
Advances in Medical and Surgical...
The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and ...
The financial costs of care are just as important—maybe more—as the physical and mental side effects and deserve equal consideration and support.— Donna Piunt
Although my diagnosis of stage IIIB melanoma 5 years ago came as a shock, in hindsight, it shouldn’t have been...!-->!-->
Melvin R. Laird
“I am greatly saddened by the death of former Congressman Melvin R. Laird, who, over the course of his distinguished career in public service, played a key role in advancing biomedical research and the mission of the National Institutes of Health (NIH). Our thoughts are...!-->!-->
Cardio-oncology has evolved in the past decade because of the explosion of cancer treatments and related cardiovascular toxicity. However, the intersection between cancer and cardiovascular disease extends beyond toxicology.— Javid J. Moslehi, MD
Reports of rare, but in some cases fatal, cardiac complications when the checkpoint inhibitors ipilimumab (Yervoy) and nivolumab (Opdivo) are used in combination should be taken seriously but should not scare patients away from potentially life-saving drugs, according to Javid J. Moslehi, MD. Dr....
George A. Komatsoulis, PhD
CancerLinQ LLC has announced that George A. Komatsoulis, PhD, will be its first Chief of Bio-Informatics. This marks another step toward the organization’s goal of making the CancerLinQ® platform the premier system for unlocking patient data from millions of...!-->!-->
In a secondary analysis from the NRG Oncology RTOG 0617 trial reported in the Journal of Clinical Oncology, Stephen G. Chun, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, and colleagues found that use of intensity-modulated vs three-dimensional...
In a study reported in the Journal of Clinical Oncology, Chakravarthy et al found that human papillomavirus (HPV)-driven tumors accounted for 4.1% of nonoropharyngeal squamous cell carcinomas of the head and neck. HPV-positive tumors were associated with poorer survival and reduced...
The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Danny N. Khalil, MD, PhD, and colleagues in Clinical Cancer Research....
Richmond T. Prehn, MD
Until 1957, the prevailing thought was that since cancers develop in normal patients, they are not recognized as foreign by the immune system. That changed when Richmond T. Prehn, MD, and his laboratory assistant, Joan Main, showed that tumors induced by chemical...!-->!-->